These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 33458843)

  • 1. Comprehensive insights into the formation of metabolites of the ghrelin mimetics capromorelin, macimorelin and tabimorelin as potential markers for doping control purposes.
    Lange T; Thomas A; Görgens C; Bidlingmaier M; Schilbach K; Fichant E; Delahaut P; Thevis M
    Biomed Chromatogr; 2021 Jun; 35(6):e5075. PubMed ID: 33458843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doping control analysis of trimetazidine and characterization of major metabolites using mass spectrometric approaches.
    Sigmund G; Koch A; Orlovius AK; Guddat S; Thomas A; Schänzer W; Thevis M
    Drug Test Anal; 2014; 6(11-12):1197-205. PubMed ID: 24913825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of ghrelin and desacyl ghrelin in human plasma and urine by means of LC-MS/MS for doping controls.
    Thomas A; Krombholz S; Wolf C; Thevis M
    Drug Test Anal; 2021 Nov; 13(11-12):1862-1870. PubMed ID: 34633773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls.
    Möller I; Wintermeyer A; Bender K; Jübner M; Thomas A; Krug O; Schänzer W; Thevis M
    Drug Test Anal; 2011 Sep; 3(9):609-20. PubMed ID: 20872894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding analytical possibilities concerning the detection of stanozolol misuse by means of high resolution/high accuracy mass spectrometric detection of stanozolol glucuronides in human sports drug testing.
    Schänzer W; Guddat S; Thomas A; Opfermann G; Geyer H; Thevis M
    Drug Test Anal; 2013; 5(11-12):810-8. PubMed ID: 23873860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass spectrometric characterization of the hypoxia-inducible factor (HIF) stabilizer drug candidate BAY 85-3934 (molidustat) and its glucuronidated metabolite BAY-348, and their implementation into routine doping controls.
    Dib J; Mongongu C; Buisson C; Molina A; Schänzer W; Thuss U; Thevis M
    Drug Test Anal; 2017 Jan; 9(1):61-67. PubMed ID: 27346747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid chromatography-high resolution/ high accuracy (tandem) mass spectrometry-based identification of in vivo generated metabolites of the selective androgen receptor modulator ACP-105 for doping control purposes.
    Thevis M; Thomas A; Piper T; Krug O; Delahaut P; Schänzer W
    Eur J Mass Spectrom (Chichester); 2014; 20(1):73-83. PubMed ID: 24881457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of GnRH and its synthetic analogues' abuse in doping control: Small bioactive peptide UPLC-MS/MS method extension by addition of in vitro and in vivo metabolism data; evaluation of LH and steroid profile parameter fluctuations as suitable biomarkers.
    Zvereva I; Dudko G; Dikunets M
    Drug Test Anal; 2018 Apr; 10(4):711-722. PubMed ID: 28777889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. lmplementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls.
    Eichner D; Van Wagoner RM; Brenner M; Chou J; Leigh S; Wright LR; Flippin LA; Martinelli M; Krug O; Schänzer W; Thevis M
    Drug Test Anal; 2017 Nov; 9(11-12):1768-1778. PubMed ID: 28378453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Automated sample preparation for the detection and confirmation of hypoxia-inducible factor stabilizers in urine.
    De Wilde L; Roels K; Deventer K; Van Eenoo P
    Biomed Chromatogr; 2021 Feb; 35(2):e4970. PubMed ID: 32840903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fully automated determination of nicotine and its major metabolites in whole blood by means of a DBS online-SPE LC-HR-MS/MS approach for sports drug testing.
    Tretzel L; Thomas A; Piper T; Hedeland M; Geyer H; Schänzer W; Thevis M
    J Pharm Biomed Anal; 2016 May; 123():132-40. PubMed ID: 26896632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doping control analysis for adrafinil and its major metabolites in human urine.
    Lu J; Wang X; Yang S; Liu X; Qin Y; Shen L; Wu Y; Xu Y; Wu M; Ouyang G
    Rapid Commun Mass Spectrom; 2009 Jun; 23(11):1592-600. PubMed ID: 19399790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultra high performance liquid chromatography tandem mass spectrometry determination and profiling of prohibited steroids in human biological matrices. A review.
    Gosetti F; Mazzucco E; Gennaro MC; Marengo E
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 May; 927():22-36. PubMed ID: 23317577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of therapeutics with growth-hormone secretagogue activity in human urine for doping control purposes.
    Thevis M; Wilkens F; Geyer H; Schänzer W
    Rapid Commun Mass Spectrom; 2006; 20(22):3393-402. PubMed ID: 17051614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fully automated dried blood spot sample preparation enables the detection of lower molecular mass peptide and non-peptide doping agents by means of LC-HRMS.
    Lange T; Thomas A; Walpurgis K; Thevis M
    Anal Bioanal Chem; 2020 Jun; 412(15):3765-3777. PubMed ID: 32300840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of doping peptides via solid-phase microelution and accurate-mass quadrupole time-of-flight LC-MS.
    Cuervo D; Loli C; Fernández-Álvarez M; Muñoz G; Carreras D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Oct; 1065-1066():134-144. PubMed ID: 28939282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass spectrometric characterization of a prolyl hydroxylase inhibitor GSK1278863, its bishydroxylated metabolite, and its implementation into routine doping controls.
    Thevis M; Milosovich S; Licea-Perez H; Knecht D; Cavalier T; Schänzer W
    Drug Test Anal; 2016 Aug; 8(8):858-63. PubMed ID: 26361079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls.
    Thevis M; Möller I; Thomas A; Beuck S; Rodchenkov G; Bornatsch W; Geyer H; Schänzer W
    Anal Bioanal Chem; 2010 Apr; 396(7):2479-91. PubMed ID: 19946680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening of over 100 drugs in horse urine using automated on-line solid-phase extraction coupled to liquid chromatography-high resolution mass spectrometry for doping control.
    Kwok WH; Choi TLS; Tsoi YYK; Leung GNW; Wan TSM
    J Chromatogr A; 2017 Mar; 1490():89-101. PubMed ID: 28215405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterization of urinary prenylamine metabolites by means of liquid chromatography-tandem mass spectrometry.
    Beuck S; Sigmund G; Koch A; Schänzer W; Pokrywka A; Kwiatkowska D; Thevis M
    Drug Test Anal; 2012 Sep; 4(9):701-16. PubMed ID: 22786790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.